Date: 2015-06-16
Type of information: IPO
Company: Axovant Sciences (Bermuda - USA - NY)
Investors:
Amount: $362 million
Funding type: IPO
Planned used:
Others: * On June 16, 2015, Axovant Sciences, a clinical-stage biopharmaceutical company, announced the completion of its initial public offering of 24,150,000 common shares, including 3,150,000 common shares sold pursuant to the full exercise of the underwriters\' previously granted option to purchase additional common shares. All of the common shares were offered by Axovant at a public offering price of $15.00 per share. The common shares of Axovant began trading under the ticker symbol \"AXON\" on June 11, 2015. The gross proceeds to Axovant from this offering, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by Axovant, were approximately $362 million. * On June 10, 2015, Axovant Sciences announced the pricing of its initial public offering of 21,000,000 common shares at a price of $15.00 per share. The common shares of Axovant Sciences Ltd. have been approved for listing on the New York Stock Exchange and are expected to begin trading under the ticker symbol \"AXON\" on June 11, 2015. All of the common shares are being offered by Axovant Sciences Ltd. In addition, Axovant Sciences Ltd. has granted the underwriters a 30-day option to purchase up to 3,150,000 additional common shares. Jefferies LLC, Evercore Group L.L.C. and RBC Capital Markets LLC are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager, and Robert W. Baird & Co. Incorporated is acting as co-manager for the offering.
Therapeutic area: Mental diseases - Neurodegenerative diseases
